Identification of KIF20A as a tumor biomarker and forwarder of clear cell renal cell carcinoma

To the Editor: Renal cell carcinoma (RCC) is one of the top 10 major cancer types in adults. Current research shows that clear cell renal cell carcinoma (ccRCC) remains a deadly tumor disease and is associated with most cancerrelated deaths. Timely diagnosis is extremely important for the treatment of tumor patients. Adjusting the treatment plan based on the results of clinical diagnostic markers has a positive effect on patient prognosis. There is still a high risk of local recurrence or distant metastasis after nephrectomy. Tyrosine kinase inhibitor (TKI) has shown encouraging efficacy in advanced ccRCC patients. Unfortunately, TKI resistance still develops and can lead to poor progression in cancer. Thus, there is an urgent need to explore more effective prognostic biomarkers and to identify novel drug targets for ccRCC therapies.